title: Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease.
abstract: OBJECTIVE
  Evidence is growing that some patients are not responsive to the antithrombotic action of aspirin. We prospectively evaluated the ability of aspirin resistance status, determined by PFA-100, to predict new thrombotic events in patients with stable ischemic cerebrovascular disease.
  
  
  METHODS
  We studied 129 consecutive patients with stroke, transient ischemic attack (TIA) or vascular cognitive impairment. We assessed relationships between aspirin resistance, risk factors for ischemic cerebrovascular disease, and occurrence of new thrombotic events (composite of stroke, TIA, myocardial infarction, and cardiovascular death).
  
  
  RESULTS
  Aspirin resistance, found in 26 (20.1%) cases, was unrelated to any of the examined vascular risk factors. During mean follow-up of 56 months, new thrombotic events occurred in 19 patients (14.7%), four with aspirin resistance (15.4%) and 15 (14.6%) without aspirin resistance (p=1.00).
  
  
  CONCLUSIONS
  Aspirin resistance determined by PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease.
authors.affiliation: Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, 20133 Milano, Italy. giorgio.boncoraglio@istituto-besta.it
authors.forename: Giorgio B
authors.initials: GB
authors.lastname: Boncoraglio
authors.forename: Antonella
authors.initials: A
authors.lastname: Bodini
authors.forename: Carla
authors.initials: C
authors.lastname: Brambilla
authors.forename: Elena
authors.initials: E
authors.lastname: Corsini
authors.forename: Maria R
authors.initials: MR
authors.lastname: Carriero
authors.forename: Eugenio A
authors.initials: EA
authors.lastname: Parati
mesh_terms: D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D003072:Cognition Disorders / Q000209:etiology / Q000503:physiopathology; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006403:Hematologic Tests; D006801:Humans; D002546:Ischemic Attack, Transient / Q000150:complications / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control*; D013927:Thrombosis / Q000150:complications / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin